WILL-COPE: Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Unknown status
CT.gov ID
NCT03827525
Collaborator
Fondation Jérôme Lejeune (Other), association autour des Williams (Other), réseau de santé Maladies Rares (Other)
5
1
20
0.2

Study Details

Study Description

Brief Summary

Patients with Williams-Beuren syndrome are eight times more likely to suffer from anxiety compared to the general population. Few therapeutic solutions are proposed to these patients. The objective of this research is to validate a cognitive and behavioral therapy anxiety protocol for patients with this syndrome.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive and Behavioral Therapy

Detailed Description

Most studies agree that anxiety disorders are more frequent in people with intellectual disabilities that in the general population. Williams syndrome (WS) is a rare disease, associated with an anxiety rate 8 times higher than in the general population. The therapeutic solutions proposed in this population remain limited, in particular concerning approaches without the use of medication. The objective of the study is to evaluate the effectiveness of a program of Cognitive and Behavioral Therapies (CBT) in Williams Syndrome (WS). For this, an ABA-type protocol will be used. It consists of evaluating the effectiveness of an interventional program longitudinally, using a single case type study. Adults patients with WS and suffering from anxiety will be recruited. They will be enrolled in a program consisting in nine sessions of a psychotherapy program targeting anxiety. There will be a pretherapy visit (day 0), nine sessions of psychotherapy (month 0 to month 5) and a visit 3 month after the end of the therapy (at month 8) : the visit of the end of the research (V10). The expected results will be to validate a psychotherapeutic program for patients with WS suffering of anxiety. This program might be extended to other patients with intellectual disability.

Study Design

Study Type:
Observational
Anticipated Enrollment :
5 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome
Actual Study Start Date :
Aug 29, 2019
Anticipated Primary Completion Date :
Apr 29, 2021
Anticipated Study Completion Date :
Apr 29, 2021

Arms and Interventions

Arm Intervention/Treatment
Cognitive and Behavioral Therapy

There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome

Behavioral: Cognitive and Behavioral Therapy
9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.

Outcome Measures

Primary Outcome Measures

  1. Likert anxiety Scale [From day 0 to month 5.]

    Repeated evaluation of his anxiety by the patient with the Likert scale. Each day, the patient quantifies his anxiety with the scale with a score from 0 to 9.

Secondary Outcome Measures

  1. Hamilton Anxiety Scale [This score will be obtained at the pre therapy visit (day 0), at the visit of the end of the therapy (month 5), and at the visit of the end of the research (month 8)]

    Hamilton anxiety scale will be realised with the patient by a clinical psychologist. It is an evaluation of the anxiety based on 14 questions and observations of the patient. The questions are rated according to the severity of the symptoms: anxious mood, depressed mood, somatic symptoms...Symptoms are evaluated using 5 degrees of severity, from absence of severity to disabling intensity. The overall score ranges from 0 to 60.

  2. Inhibition score [This score will be obtained at the pre therapy visit (day 0), at the visit of the end of the therapy (month 5), and at the visit of the end of the research (month 8)]

    the inhibition will be assessed with the Go/no Go test which last 3 minutes.

  3. salivary cortisol [This sample will be obtained at the pretherapy visit (day 0), and at the visit of the end of the research (month 8).]

    The sample will be realised by a nurse. The level of cortisol is related to the level of stress.

  4. WHOQOL-BREF score [This score will be obtained at the pre therapy visit (day 0), at the visit of the end of the therapy (month 5), and at the visit of the end of the research (month 8).]

    this scale evaluates the quality of life with 26 questions. For each question, the quality of life is evaluated from very low to very high (5 levels). It will be completed by the person of trust.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Williams Syndrome

  • Complaint about anxiety

  • 18 years old and more

  • Score of 7 or more at the CELF-4 (it is a scale assessing the language)

  • informed consent signed

Exclusion Criteria:
  • Scoring less than 7 at the CELF-4

  • Hearing impairment

  • Visual impairment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Arnaud de villeneuve Hospital Montpellier Hérault France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier
  • Fondation Jérôme Lejeune
  • association autour des Williams
  • réseau de santé Maladies Rares

Investigators

  • Principal Investigator: Natacha LEHMAN, Department of Medical Genetics

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT03827525
Other Study ID Numbers:
  • RECHMPL18_0375
First Posted:
Feb 1, 2019
Last Update Posted:
Oct 18, 2019
Last Verified:
Jan 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2019